P21 WAF1/Cip1/Sdi1 knockout mice respond to doxorubicin with reduced cardiotoxicity

Toxicology and Applied Pharmacology

Volumn 257, Issue 1, 2011, Pages 102-110

  Terrand, Jerome ^a   Xu, Beibei ^a   Morrissy, Steve ^a   Dinh, Thai Nho ^a   Williams, Stuart ^b   Chen, Qin M ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antioxidant enzymes; Cardiomyopathy; Cell cycle inhibitor; Inflammatory response

Indexed keywords

CATALASE; DOXORUBICIN; GAMMA INTERFERON; GLUTATHIONE PEROXIDASE; INTERLEUKIN 12; INTERLEUKIN 6; MESSENGER RNA; PROTEIN P21; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; GENE INACTIVATION; HEART MUSCLE; MALE; MOUSE; NONHUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; CATALASE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOXORUBICIN; ENZYME INDUCTION; FLOW CYTOMETRY; GLUTATHIONE PEROXIDASE; MICE; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPEROXIDE DISMUTASE;

ANIMALIA; MUS;

EID: 81255137895     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.08.024     Document Type: Article

References (48)

1. Ahuja P., Sdek P., MacLellan W.R. Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiol. Rev. 2007, 87:521-544.
2. Anversa P., Kajstura J., Leri A., Bolli R. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation 2006, 113:1451-1463.
3. Anversa P., Leri A., Kajstura J. Cardiac regeneration. J. Am. Coll. Cardiol. 2006, 47:1769-1776.
4. Bahl R., Arora S., Nath N., Mathur M., Shukla N.K., Ralhan R. Novel polymorphism in p21 (waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer. Oncogene 2000, 19:323-328.
5. Barth E., Stammler G., Speiser B., Schaper J. Ultrastructural quantitation of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man. J. Mol. Cell. Cardiol. 1992, 24:669-681.
6. Boffa G.M., Zaninotto M., Sartor R., Mion M., Berton A., Pasqualetto C., Razzolini R., Plebani M. Interleukin-6 and tumor necrosis factor-alpha as biochemical markers of heart failure: a head-to-head clinical comparison with B-type natriuretic peptide. J. Cardiovasc. Med. (Hagerstown) 2009, 10:758-764.
7. Bradham W.S., Bozkurt B., Gunasinghe H., Mann D., Spinale F.G. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc. Res. 2002, 53:822-830.
8. Bristow M.R., Thompson P.D., Martin R.P., Mason J.W., Billingham M.E., Harrison D.C. Early anthracycline cardiotoxicity. Am. J. Med. 1978, 65:823-832.
9. Chatterjee K., Zhang J., Honbo N., Karliner J.S. Doxorubicin cardiomyopathy. Cardiology 2010, 115:155-162.
10. Chen Q., Alexander D., Sun H., Xie L., Lin Y., Terrand J., Morrissy S., Purdom S. Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: induction of anti-apoptosis, antioxidant and detoxification genes. Mol. Pharm. 2005, 67:1861-1873.
11. Doroshow J.H., Davies K.J. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J. Biol. Chem. 1986, 261:3068-3074.
12. Friedman M.A., Bozdech M.J., Billingham M.E., Rider A.K. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA 1978, 240:1603-1606.
13. Fujihira S., Yamamoto T., Matsumoto M., Yoshizawa K., Oishi Y., Fujii T., Noguchi H., Mori H. The high incidence of atrial thrombosis in mice given doxorubicin. Toxicol. Pathol. 1993, 21:362-368.
14. Gao J., Xiong Y., Ho Y.S., Liu X., Chua C.C., Xu X., Wang H., Hamdy R., Chua B.H. Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity. Biochim. Biophys. Acta 2008, 1783:2020-2029.
15. Gaudin P.B., Hruban R.H., Beschorner W.E., Kasper E.K., Olson J.L., Baughman K.L., Hutchins G.M. Myocarditis associated with doxorubicin cardiotoxicity. Am. J. Clin. Pathol. 1993, 100:158-163.
16. Gutierrez P.L. The role of NAD(P)H oxidoreductase (DT-Diaphorase) in the bioactivation of quinone-containing antitumor agents: a review. Free Radic. Biol. Med. 2000, 29:263-275.
17. Hassink R.J., Pasumarthi K.B., Nakajima H., Rubart M., Soonpaa M.H., de la Riviere A.B., Doevendans P.A., Field L.J. Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction. Cardiovasc. Res. 2008, 78:18-25.
18. Heymans S., Hirsch E., Anker S.D., Aukrust P., Balligand J.L., Cohen-Tervaert J.W., Drexler H., Filippatos G., Felix S.B., Gullestad L., Hilfiker-Kleiner D., Janssens S., Latini R., Neubauer G., Paulus W.J., Pieske B., Ponikowski P., Schroen B., Schultheiss H.P., Tschope C., Van Bilsen M., Zannad F., McMurray J., Shah A.M. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2009, 11:119-129.
19. Kajstura J., Urbanek K., Rota M., Bearzi C., Hosoda T., Bolli R., Anversa P., Leri A. Cardiac stem cells and myocardial disease. J. Mol. Cell. Cardiol. 2008, 45:505-513.
20. Kang Y.J., Chen Y., Epstein P.N. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J. Biol. Chem. 1996, 271:12610-12616.
21. Kotamraju S., Konorev E.A., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J. Biol. Chem. 2000, 275:33585-33592.
22. Kuhn D.E., Roy S., Radtke J., Khanna S., Sen C.K. Laser microdissection and capture of pure cardiomyocytes and fibroblasts from infarcted heart regions: perceived hyperoxia induces p21 in peri-infarct myocytes. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H1245-H1253.
23. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
24. Lips D.J., van der Nagel T., Steendijk P., Palmen M., Janssen B.J., van Dantzig J.M., de Windt L.J., Doevendans P.A. Left ventricular pressure-volume measurements in mice: comparison of closed-chest versus open-chest approach. Basic Res. Cardiol. 2004, 99:351-359.
25. Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 1991, 324:808-815.
26. Ludke A.R., Al-Shudiefat A.A., Dhingra S., Jassal D.S., Singal P.K. A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Can. J. Physiol. Pharm. 2009, 87:756-763.
27. MacGowan G.A., Mann D.L., Kormos R.L., Feldman A.M., Murali S. Circulating interleukin-6 in severe heart failure. Am. J. Cardiol. 1997, 79:1128-1131.
28. Mehta J.L., Li D.Y. Inflammation in ischemic heart disease: response to tissue injury or a pathogenetic villain?. Cardiovasc. Res. 1999, 43:291-299.
29. Merched A.J., Chan L. Absence of p21Waf1/Cip1/Sdi1 modulates macrophage differentiation and inflammatory response and protects against atherosclerosis. Circulation 2004, 110:3830-3841.
30. Myers C.E., McGuire W.P., Liss R.H., Ifrim I., Grotzinger K., Young R.C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977, 197:165-167.
31. Nemoto S., Defreitas G., Carabello B. Cardiac catheterization technique in a closed-chest murine model. Contemporary Topics 2003, 34-38. American Association for Laboratory Animal Surgery.
32. Orlic D., Kajstura J., Chimenti S., Jakoniuk I., Anderson S.M., Li B., Pickel J., McKay R., Nadal-Ginard B., Bodine D.M., Leri A., Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature 2001, 410:701-705.
33. Plenz G., Song Z.F., Tjan T.D., Koenig C., Baba H.A., Erren M., Flesch M., Wichter T., Scheld H.H., Deng M.C. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur. J. Heart Fail. 2001, 3:415-421.
34. Qiu H., Dai H., Jain K., Shah R., Hong C., Pain J., Tian B., Vatner D.E., Vatner S.F., Depre C. Characterization of a novel cardiac isoform of the cell cycle-related kinase that is regulated during heart failure. J. Biol. Chem. 2008, 283:22157-22165.
35. Ralhan R., Agarwal S., Mathur M., Wasylyk B., Srivastava A. Association between polymorphism in p21 (Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer. Clin. Cancer Res. 2000, 6:2440-2447.
36. Ring R.H., Valo Z., Gao C., Barish M.E., Singer-Sam J. The Cdkn1a gene (p21Waf1/Cip1) is an inflammatory response gene in the mouse central nervous system. Neurosci. Lett. 2003, 350:73-76.
37. Rodriguez I., Coto E., Reguero J.R., Gonzalez P., Andres V., Lozano I., Martin M., Alvarez V., Moris C. Role of the CDKN1A/p21, CDKN1C/p57, and CDKN2A/p16 genes in the risk of atherosclerosis and myocardial infarction. Cell Cycle 2007, 6:620-625.
38. Roy S., Khanna S., Bickerstaff A.A., Subramanian S.V., Atalay M., Bierl M., Pendyala S., Levy D., Sharma N., Venojarvi M., Strauch A., Orosz C.G., Sen C.K. Oxygen sensing by primary cardiac fibroblasts: a key role of p21 (Waf1/Cip1/Sdi1). Circ. Res. 2003, 92:264-271.
39. Roy S., Khanna S., Rink T., Radtke J., Williams W.T., Biswas S., Schnitt R., Strauch A.R., Sen C.K. P21waf1/cip1/sdi1 as a central regulator of inducible smooth muscle actin expression and differentiation of cardiac fibroblasts to myofibroblasts. Mol. Biol. Cell 2007, 18:4837-4846.
40. Staalesen V., Knappskog S., Chrisanthar R., Nordgard S.H., Lokkevik E., Anker G., Ostenstad B., Lundgren S., Risberg T., Mjaaland I., Gram I.T., Kristensen V.N., Borresen-Dale A.L., Lillehaug J.R., Lonning P.E. The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer. Clin. Cancer Res. 2006, 12:6000-6004.
41. Suleiman M., Khatib R., Agmon Y., Mahamid R., Boulos M., Kapeliovich M., Levy Y., Beyar R., Markiewicz W., Hammerman H., Aronson D. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J. Am. Coll. Cardiol. 2006, 47:962-968.
42. Sun X., Zhou Z., Kang Y.J. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Cancer Res. 2001, 61:3382-3387.
43. van den Borne S.W., Diez J., Blankesteijn W.M., Verjans J., Hofstra L., Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat. Rev. Cardiol. 2010, 7:30-37.
44. Wagayama H., Shiraki K., Sugimoto K., Ito T., Fujikawa K., Yamanaka T., Takase K., Nakano T. High expression of p21WAF1/CIP1 is correlated with human hepatocellular carcinoma in patients with hepatitis C virus-associated chronic liver diseases. Hum. Pathol. 2002, 33:429-434.
45. Xie H.L., Su Q., He X.S., Liang X.Q., Zhou J.G., Song Y., Li Y.Q. Expression of p21(WAF1) and p53 and polymorphism of p21(WAF1) gene in gastric carcinoma. World J. Gastroenterol. 2004, 10:1125-1131.
46. Yang B., Larson D.F., Watson R. Age-related left ventricular function in the mouse: analysis based on in vivo pressure-volume relationships. Am. J. Physiol. 1999, 277:H1906-H1913.
47. Yao H., Yang S.R., Edirisinghe I., Rajendrasozhan S., Caito S., Adenuga D., O'Reilly M.A., Rahman I. Disruption of p21 attenuates lung inflammation induced by cigarette smoke, LPS, and fMLP in mice. Am. J. Respir. Cell Mol. Biol. 2008, 39:7-18.
48. Yndestad A., Damas J.K., Oie E., Ueland T., Gullestad L., Aukrust P. Systemic inflammation in heart failure-the whys and wherefores. Heart Fail. Rev. 2006, 11:83-92.